Free Trial
Your Rate Never Goes Up! Save $100 a Year on MarketBeat All Access
Upgrade Now
Claim MarketBeat All Access Sale Promotion
NASDAQ:SABS

SAB Biotherapeutics Q3 2026 Earnings Date & Estimates

SAB Biotherapeutics logo
$2.84 -0.20 (-6.58%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$2.84 0.00 (-0.18%)
As of 10/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

SAB Biotherapeutics is estimated to report Q3 2026 earnings on Friday, November 13, 2026, before market opens. The conference call is scheduled for November 6, 2026 at 9:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
9:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from SAB Biotherapeutics in Q3 2026

SAB Biotherapeutics is expected to post earnings of -$0.27 per share on revenue of $0.13 million. In the same quarter a year earlier SAB Biotherapeutics reported -$0.21 per share. SAB Biotherapeutics last reported on August 6, 2026, posting -$0.28 per share and beating the -$0.2830 consensus estimate. SAB Biotherapeutics has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.27
Expected Revenue
$0.13 million
Prior-Year EPS
-$0.21

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.28 (Beat by +$0.0030)
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

SAB Biotherapeutics Q3 2026 Earnings FAQ

SAB Biotherapeutics (NASDAQ:SABS) is estimated to report Q3 2026 earnings on Friday, November 13, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

SAB Biotherapeutics' Q3 2026 earnings conference call is scheduled for Friday, November 6, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect SAB Biotherapeutics to post earnings of -$0.27 per share for Q3 2026.

The consensus revenue estimate for SAB Biotherapeutics is $0.13 million for Q3 2026.

SAB Biotherapeutics Earnings Headlines

SAB Biotherapeutics Says SAB-142 Receives FDA Fast Track Designation in Type 1 Diabetes
October 14, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/sab-biotherapeutics-says-sab-142-131715443.html
SAB BIO to Participate in Chardan 10th Annual Healthcare Conference
October 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/14/3380732/0/en/sab-bio-to-participate-in-chardan-10th-annual-healthcare-conference.html
Elon Musk’s One Stock Retirement Plan
Stanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding two or three asymmetric home runs. Analyst Jeff Brown says he has identified a new one, a single stock he calls Elon Musk's One Stock Retirement Plan.tc pixel
October 24 at 1:00 AM  |  Brownstone Research (Ad)
SAB Biotherapeutics, Inc. Receives FDA Fast Track Designation For SAB-142 In Stage 3 Type 1 Diabetes
October 13, 2026  |  marketscreener.comM
SAB Bio Wins FDA Fast Track Status For SAB-142 In Type 1 Diabetes; Stock Up
October 13, 2026  |  rttnews.comhttps://www.rttnews.com/3698552/sab-bio-wins-fda-fast-track-status-for-sab-142-in-type-1-diabetes-stock-up.aspx
SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes
October 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/13/3379679/0/en/sab-bio-receives-fda-fast-track-designation-for-sab-142-in-stage-3-type-1-diabetes.html
See More SAB Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like SAB Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SAB Biotherapeutics and other key companies, straight to your email.

About SAB Biotherapeutics

SAB Biotherapeutics (NASDAQ:SABS) is a biotechnology company focused on developing fully human polyclonal antibody medicines for infectious diseases, immune disorders and other conditions where targeted immune responses may provide therapeutic benefits. The company is based in Sioux Falls, South Dakota.

SAB Biotherapeutics uses its DiversitAb platform, which involves genetically engineered cattle capable of producing antibodies with human immune-system characteristics. Antibodies are collected from the animals’ plasma and processed for potential use as treatments, allowing the company to pursue antibody products without relying solely on conventional human donor sources.

The company has developed a pipeline that has included SAB-185, an investigational antibody therapy directed at SARS-CoV-2, as well as programs targeting influenza and autoimmune or immune-mediated diseases. Its research and development activities have included collaborations with government agencies, academic institutions and pharmaceutical organizations. SAB Biotherapeutics became a publicly traded company on Nasdaq through a business combination completed in 2021.

View SAB Biotherapeutics Profile
Earnings Tools